Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18843387 | 0.95 | ALOX5 (0.37) | GCGRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL18610228 | 0.94 | ALOX5 (0.36) | GCGRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL19116270 | 0.94 | ALOX5 (0.36) | GCGRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL19116363 | 0.94 | GCGR (0.36) | GCGRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL18545931 | 0.80 | LMNA (0.31) | MAPT | |
| SCHEMBL18842870 | 0.76 | KDM4E (0.32) | — | |
| SCHEMBL22359954 | 0.76 | TYR (0.43) | ALOX5MEN1TP53CYP3A4MAPT | |
| SCHEMBL19116416 | 0.73 | ALOX5 (0.36) | GCGRALOX5MEN1TP53CYP3A4 | |
| SCHEMBL22837887 | 0.73 | — | — | |
| SCHEMBL25700623 | 0.71 | TNF (0.36) | MAPTTYRHTTTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10487173-B2 | Fluorine substitution influence on benzo[2,1,3]thiodiazole based polymers for field-effect transistor applications | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-11-26 | — | — | US | disclosed |
| US-10167362-B2 | Doping-induced carrier density modulation in polymer field-effect transistors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170069859-A1 | DOPING-INDUCED CARRIER DENSITY MODULATION IN POLYMER FIELD-EFFECT TRANSISTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10487173-B2 | Fluorine substitution influence on benzo[2,1,3]thiodiazole based polymers for field-effect transistor applications | SLCO1B3, SLCO2B1, SLCO4C1 | GCGR 3659/4885ALOX5 1587/4885MEN1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.